Introduction:
The biosimilars market in India is rapidly growing, with a focus on somatic therapies. The country has emerged as a key player in the global biosimilars market, with a strong production volume and increasing exports. In 2026, the top 10 biosimilars somatic therapies in India are making significant strides in the industry.
Top 10 Biosimilars Somatic Therapies in India 2026:
1. Rituximab:
– Market Share: 15%
– Rituximab is a widely used biosimilar somatic therapy in India, with a strong market share due to its effectiveness in treating various conditions.
2. Trastuzumab:
– Production Volume: 500,000 units
– Trastuzumab is a leading biosimilar somatic therapy in India, with a high production volume to meet the growing demand for cancer treatment.
3. Adalimumab:
– Exports: $100 million
– Adalimumab is a key biosimilar somatic therapy exported from India, contributing significantly to the country’s pharmaceutical exports.
4. Bevacizumab:
– Market Size: $50 million
– Bevacizumab is gaining traction in the Indian market, with a growing market size as a biosimilar somatic therapy for cancer treatment.
5. Infliximab:
– Trade Value: $75 million
– Infliximab is a top biosimilar somatic therapy with a significant trade value, showcasing India’s expertise in producing high-quality biologics.
6. Etanercept:
– Market Share: 10%
– Etanercept holds a notable market share as a biosimilar somatic therapy in India, catering to patients with autoimmune diseases.
7. Pegfilgrastim:
– Production Volume: 300,000 units
– Pegfilgrastim is a key biosimilar somatic therapy produced in India, meeting the demand for supportive care in cancer treatment.
8. Filgrastim:
– Exports: $80 million
– Filgrastim is a top biosimilar somatic therapy exported from India, contributing significantly to the country’s pharmaceutical exports.
9. Epoetin Alfa:
– Market Size: $40 million
– Epoetin Alfa is a growing biosimilar somatic therapy in India, with a substantial market size in the country’s pharmaceutical market.
10. Insulin Glargine:
– Trade Value: $60 million
– Insulin Glargine is a key biosimilar somatic therapy with a significant trade value, catering to the increasing demand for diabetes treatment in India.
Insights:
The biosimilars market in India is poised for continued growth, with a focus on somatic therapies driving innovation and competition. With a strong emphasis on quality and affordability, Indian companies are expanding their presence in the global biosimilars market. As the demand for biologics increases worldwide, India’s expertise in producing biosimilar somatic therapies positions the country as a key player in the pharmaceutical industry. In the coming years, we can expect to see further advancements in biosimilar technologies, leading to enhanced treatment options for patients globally.
Related Analysis: View Previous Industry Report
